NCT00312546 is a Phase 1 clinical trial of Enfuvirtide in HIV Infections, sponsored by University of North Carolina, Chapel Hill.

Who is sponsoring NCT00312546?

NCT00312546 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT00312546?

Interventions in NCT00312546: Enfuvirtide, Valproic acid.

What condition does NCT00312546 study?

NCT00312546 studies HIV Infections.

Is NCT00312546 still recruiting?

NCT00312546 is currently terminated. Last updated 11 May 2012.

Last reviewed 2012-05-11 · How we verify

NCT00312546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhibiting Histone Deacetylase: Toward Eradication of HIV

Terminated Phase 1 Last updated 11 May 2012

What this trial tests

Phase 1 trial testing Enfuvirtide in HIV Infections in 14 participants. Terminated before completion.

Timeline

1 June 2006

Primary endpoint
1 April 2009

1 October 2009

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	1 June 2006
Primary completion	1 April 2009
Estimated completion	1 October 2009
Sites	1 location across United States

Drugs / interventions tested

Enfuvirtide (ENFUVIRTIDE) — full drug profile →
Valproic acid (valproic acid) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Frequencies of replication-competent HIV detected in resting CD4 cells
Time frame: At pre-entry and Week 0 to Weeks 12 and 16

Sponsor's own description

A histone deacetylase (HDAC) inhibitor is a class of drug that interferes with the function of HDAC, an enzyme that hides HIV within inactive CD4 cells. These drugs are normally used to treat seizures and other nervous system problems but have been found to work against HIV. The purpose of this study is to investigate the efficacy of valproic acid (VPA), an HDAC inhibitor, in treating HIV infected adults using anti-HIV drugs.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Trials with 'epigenetic' drugs: an update.
Nebbioso A, Carafa V, Benedetti R, Altucci L. · · 2012 · cited 162× · PMID 23103179 · DOI 10.1016/j.molonc.2012.09.004
Nanotechnology approaches to eradicating HIV reservoirs.
Cao S, Woodrow KA. · · 2019 · cited 37× · PMID 29879528 · DOI 10.1016/j.ejpb.2018.06.002
T-cell therapies for HIV: Preclinical successes and current clinical strategies.
Patel S, Jones RB, Nixon DF, Bollard CM. · · 2016 · cited 32× · PMID 27265874 · DOI 10.1016/j.jcyt.2016.04.007

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00312546 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 11 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00312546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing